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ABSTRACT: â-Lactams exert their antibiotic action through their inhibition of bacterial DD-peptidases
(penicillin-binding proteins). Bacteria, in general, carry several such enzymes localized on the outside of
their cell membrane to catalyze the final step in cell wall (peptidoglycan) synthesis. They have been
classified into two major groups, one of high molecular weight, the other of low. Members of the former
group act as transpeptidases in ViVo, and their inhibition by â-lactams leads to cessation of bacterial
growth. The latter group consists of DD-carboxypeptidases, and their inhibition by â-lactams is generally
not fatal to bacteria. We have previously shown that representatives of the former group are ineffective
at catalyzing the hydrolysis/aminolysis of peptidoglycan-mimetic peptides in Vitro [Anderson et al. (2003)
Biochem. J. 373, 949-955]. The theme of these experiments is expanded in the present paper where we
describe the synthesis of a series of â-lactams (penicillins and cephalosporins) containing peptidoglycan-
mimetic side chains and the kinetics of their inhibition of a panel of penicillin-binding proteins spanning
the major classes (Escherichia coli PBP 2 and PBP 5, Streptococcus pneumoniae PBP 1b, PBP 2x and
PBP 3, the Actinomadura R39 DD-peptidase, and the Streptomyces R61 DD-peptidase). The results of
these experiments mirror and expand the previous results with peptides. Neither peptides nor â-lactams
with appropriate peptidoglycan-mimetic side chains react with the solubilized constructs of membrane-
bound penicillin binding proteins (the first five enzymes above) at rates exceeding those of generic
analogues. Such peptides and â-lactams do react at greatly enhanced rates with certain soluble low molecular
weight enzymes (R61 and R39 DD-peptidases). The former result is unexpected and interesting. Why do
the majority of penicillin-binding proteins not recognize elements of local peptidoglycan structure? Possible
answers are discussed. That this question needs to be asked casts fascinating shadows on current studies
of penicillin-binding proteins for new drug design.
The biosynthesis of the bacterial cell wall has been
intensively studied as a source of antibiotic targets. Although
a number of inhibitors of the constitutive enzymes have been
described (1-3), the most successful as antibiotics are the
â-lactams. These compounds inhibit enzymes that catalyze
the final transpeptidation step where the disaccharide pen-
tapeptide monomer is incorporated into the cell wall (4).
These enzymes are variously referred to as D-alanyl-D-alanine
transpeptidases, DD-peptidases, and penicillin-binding pro-
teins (PBPs1).
Bacteria generally maintain several PBPs in their cell
membranes, each of which normally plays a different role
in cell wall peptidoglycan synthesis (5, 6). Structural studies
of these enzymes, particularly by Ghuysen and co-workers,
led to a classification scheme based on amino acid sequence
homologies (7). First, two groups were distinguished, one
of high molecular weight (HMW), the other of low (LMW).
Each of these groups was divided into three classes: A, B,
and C. High molecular weight classes A and B act as
transpeptidases in ViVo and are the killing targets of â-lactam
antibiotics. Low molecular weight classes A-C contain
D-alanyl-D-alanine carboxypeptidases. The latter enzymes are
also inhibited by â-lactams, but their inhibition is not usually
fatal to bacteria. Resistance to â-lactams can arise through
PBP mutations and homologous recombinations (8, 9).
Most PBPs, particularly the essential HMW class A and
B enzymes, are attached to the outer leaflet of the cell
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membrane by means of a short peptide extension. Deletion
of this extension leads to soluble globular proteins that retain
their penicillin-binding ability (7). X-ray crystal structures
of several of these solubilized constructs have been obtained
in recent years including examples of all the major classes
referred to above (10-16), as well as of â-lactam-resistant
mutants (17-19). These structures have revealed that PBP
active sites have much in common, sharing similar functional
groups and, presumably, similar mechanisms of catalysis
(20). Less obvious from the structures, to date, are the sources
of substrate structural specificity. Although the natural
substrates of these enzymes must be, at least, oligopeptides,
and although there is evidence in the structures for extended
binding surfaces/clefts, there is little molecular detail avail-
able on how such substrates occupy the active sites in a
productive manner.
The assertion contained in the last sentence of the previous
paragraph is likely to be related to the observation that many
PBPs, and particularly the essential HMW class A and B
enzymes, do not, as solubilized constructs in Vitro, catalyze
the hydrolysis of peptidoglycan-mimetic peptides at any
appreciable rate (21-23). Stated more directly, there is
currently no known example of a HMW PBP efficiently
catalyzing the hydrolysis and/or aminolysis of a peptidogly-
can-mimetic peptide in Vitro. Particularly relevant and well-
studied examples here would be PBP 1b of Escherichia coli
(23-25) and PBP 2x of Streptococcus pneumoniae (26, 27).
Class A LMW enzymes, such as E. coli PBP 5, also show
very modest reactivity with peptides (28), even those
including peptidoglycan-mimetic structure (29, 30). Signifi-
cantly higher peptidase activities have been observed with
one particular LMW class C enzyme, Neisseria gonorrhoeae
PBP 3 (31), but not, interestingly, in reaction with pepti-
doglycan-mimetic peptides (29).
Strikingly, however, despite the statements above, solu-
bilized PBPs appear to be covalently inhibited by generic
â-lactams at rates comparable to the analogous rates in ViVo,
after allowance is made, in the latter case, for permeability
barriers (32, 33).
The stem peptides of E. coli and S. pneumoniae have
structures 1 and 2, respectively. We have previously shown
that peptides 3 and 4 are not appreciably hydrolyzed by E.
coli PBP 2 (HMW, class B) and PBP 5 (LMW, class A);
nor are 5 and 6 hydrolyzed by S. pneumoniae PBP 2x
(HMW, class B) (29). On the other hand, we have discovered
two cases where efficient turnover of peptidoglycan-mimetic
peptides is evident (29, 34). The peptide 7, a direct mimic
of the N-terminus of the Streptomyces stem peptide 8, is an
excellent substrate of the LMW class B DD-peptidase of
Streptomyces R61 (kcat ) 69 s-1, Km ) 7.9 íM, kcat/Km )
8.7  106 s-1 M-1). Similarly, the LMW class C DD-
peptidase of Actinomadura R39, where the stem peptide has
structure 9, is a very effective catalyst of hydrolysis of the
peptide 3 (kcat ) 7.4 s-1, Km ) 1.3 íM, kcat/Km ) 5.7  106
s-1 M-1). Neither of these enzymes, however, is a particularly
effective catalyst of hydrolysis of the peptides 6 and 4,
respectively (kcat/Km values of 270 s-1 M-1 and 2900 s-1
M-1, respectively (29)), suggesting that, in these cases at
least, substrate specificity derives from the stem peptide
N-terminus; this terminus, of course, represents the major
source of variation in bacterial stem peptides (35).
X-ray crystal structures of the peptide 7 bound at the active
site of the R61 DD-peptidase clearly showed the structural
basis of the striking substrate specificity described above:
the hydrophobic aminopimelate methylene chain is accom-
modated in a hydrophobic pocket while specific polar
interactions with the enzyme are present at the N-terminus
(36).
It is now generally appreciated that â-lactam antibiotics,
such as the penicillins (10), rapidly and specifically acylate
DD-peptidases because of their chemical reactivity and
resemblance to the tetrahedral intermediates/transition states
traversed in the hydrolysis or aminolysis of a D-alanyl-D-
alanine peptide (11) (4, 37). One might expect that if a
peptidoglycan-specific side chain R in 11 were important to
peptide binding and reactivity, then the same side chain on
the â-lactam 10 would demonstrate comparable specificity.
This has been demonstrated to be true for the penicillin 12,
which is a powerful inhibitor (ki ) 1.0  107 s-1 M-1) of
the R61 DD-peptidase (38). A crystal structure of the
â-lactam/enzyme complex shows the side chain of 12 bound
to the active site in exactly the same way as that of the
peptide 7 (39).
The reaction of â-lactams with PBPs involves acylation
of the active site serine hydroxyl group (40). Largely because
of steric hindrance (20), the acyl-enzyme thus formed is inert
to hydrolysis; hence the antibiotic activity of â-lactams.
Although, as described above, PBPs in Vitro are not, in
general, significantly reactive with peptides, they are, in
general, acylated by â-lactams at appreciable rates, probably
because of the intrinsically higher chemical reactivity of
â-lactams than peptides (although the closer structural
resemblance of 10 to a high energy intermediate than to a
peptide may be more important). In order to further probe
the specificity of PBPs for peptidoglycan-mimetic structural
elements, we have expanded the theme of 12 to representa-
tives of each of the PBP classes described above. Specifi-
cally, we describe the synthesis of the â-lactams 13-18. The
rates of inhibition of E. coli PBP 2 and PBP 5 by 13-16, S.
pneumoniae PBP 1b, 2x, and 3 by 17 and 18, and the
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Actinomadura R39 DD-peptidase by 13-15 are then de-




6-â(D-R-Aminopimelyl)-aminopenicillanic acid (13) (Scheme
1).
N-(p-Nitrobenzyloxycarbonyl)-D-R-aminopimelic Acid. D-R-
Aminopimelic acid (41) (3.68 g, 0.021 mol) was dissolved
in 2 M NaOH (21 mL, 0.042 mol), and dioxane (9 mL) was
added. This solution was cooled to 0 °C with vigorous
stirring while a solution of p-nitrobenzyl chloroformate (13.5
g, 0.06 mol) in dioxane (69 mL) and a solution of 2 M NaOH
(42 mL, 0.084 mol) was added in five equal portions
alternately, beginning with p-nitrobenzyl chloroformate, and
with a 15 min delay after each set of additions. After the
final addition, the resulting mixture was stirred at room
temperature for 30 min. The crystalline byproduct, bis(p-
nitrophenyl) carbonate, was removed by filtration and washed
with water (70 mL). The filtrate and washings were combined
and extracted with ethyl acetate. The aqueous layer was
acidified to pH 2.5 and extracted with ethyl acetate (90 mL).
This ethyl acetate extract was washed with saturated NaCl,
dried over MgSO4, and evaporated to dryness, leaving a
yellow oil (5.84 g, yield 79%). 1H NMR (d6-DMSO) ä: 1.2-
1.4 (2H, m), 1.40-1.56 (2H, m), 1.6-1.8 (2H, m), 2.2 (2H,
t, J ) 6.9 Hz), 3.9 (1H, m), 5.20 (2H, s), 7.62 (2H, d, J )
9.4 Hz), 7.76 (1H, d, J ) 7.7 Hz), 8.25 (2H, d, J ) 9.4 Hz).
p-Nitrobenzyl N-(p-Nitrobenzyloxycarbonyl)-D-R-ami-
nopimelate. To a solution of N-(p-nitrobenzyloxycarbonyl)-
D-R-aminopimelic acid (5.81 g, 16.4 mmol) in DMF (41 mL)
at 75-85 °C (internal temperature) was added dicyclohexy-
lamine (3.3 mL, 16.4 mmol), and the resulting solution was
stirred for 5 min. A solution of p-nitrobenzyl bromide (3.19
g, 14.8 mmol) in DMF (9 mL) was then added in a single
portion. Within seconds, a precipitate separated. The mixture
was immediately cooled to room temperature, and ethyl
acetate was added. The precipitate was removed by filtration,
and the filtrate was washed with water and saturated NaCl,
dried (MgSO4), and evaporated in Vacuo to leave a yellow
oil (7.94 g). This was further purified by two silica gel
columns using 40:60 and 50:50 acetone/hexane respectively;
yield 2.47 g (39%). 1H NMR (d6-DMSO) ä: 1.2-1.4 (2H,
m), 1.40-1.56 (2H, m), 1.6-1.8 (2H, m), 2.2 (2H, t, J )
6.9 Hz), 4.12 (1H, m), 5.2 (2H, ABq, J ) 3.0 Hz), 5.28
(2H, s), 7.59 (2H, d, J ) 8.9 Hz), 7.62 (2H, d, J ) 8.9 Hz),
8.0 (1H, d, J ) 8.2 Hz), 8.2 (4H, d, J ) 8.9 Hz).
Bis(p-nitrobenzyl) 6-â[N-(p-Nitrobenzyloxycarbonyl)-D-R-
aminopimelyl]-aminopenicillanate. p-Nitrobenzyl N-(p-ni-
trobenzyloxycarbonyl)-D-R-aminopimelate (100 mg, 0.20
mmol) and p-nitrobenzyl 6-aminopenicillanate (42) (0.054
g, 0.148 mmol) were dissolved in 0.73 mL of anhydrous
DMF and cooled to 0 °C in an ice bath. To this solution
were added 1-hydroxybenzotriazole (0.0273 g, 0.208 mmol)
and dicyclohexylcarbodimide (0.0341 g, 0.178 mmol), and
the reaction mixture was stirred for 3 h at room temperature;
it was then evaporated to dryness with a vacuum pump. The
residue was dissolved in ethyl acetate and washed succes-
sively with equal portions of 10% aqueous citric acid, water,
saturated aqueous NaHCO3, water, and brine. The organic
layer was dried over sodium sulfate and evaporated to
dryness. The product was purified by preparative TLC on
silica gel with 50/50 acetone/hexane as solvent; yield 53 mg
(40%). 1H NMR (d6-DMSO) ä: 1.20-1.26 (2H, m), 1.36-
1.46 (2H, m), 1.45 (3H, s), 1.54-1.66 (2H, m), 1.64 (3H,
s), 2.23 (2H, t, overlapping solvent peak), 4.27 (1H, m), 4.54
(1H, s), 5.22 (2H, s), 5.30 (2H, s), 5.35 (2H, s), 5.48 (1H, d,
J ) 3.8 Hz), 5.60 (1H, dd, J ) 3.8, 7.5 Hz), 7.54-7.62
(5H, m), 7.66 (1H, d, J ) 8.6 Hz), 8.26 (1H, d, J ) 8.6 Hz),
8.16-8.25 (5H, m).
6-â(D-R-Aminopimelyl)-aminopenicillanic acid (13). The
triprotected penicillin from above (27.1 mg, 30.3 ímol) was
dissolved in a solution of NaHCO3 (5.09 mg, 60.6 ímol) in
THF (3.1 mL) and water (3.1 mL); 10% Pd/C (54.2 mg)
was then added and the mixture hydrogenated under 1 atm
pressure at room temperature for 2.5 h. The suspension was
filtered through a Celite pad into a cooled flask, and the
filtered solid was washed with ethanol (3.1 mL) and water
(3.1 mL). The combined filtrate was extracted with diethyl
ether (2  3.1 mL) and the aqueous layer freeze-dried,
yielding a colorless solid. The product, as a sodium salt, was
initially purified by Sephadex G-10 column chromatography
(eluent water) in 26 mg yield. A final purification step,
carried out as the product was required, involved hplc (elution
by 2% methanol in 0.03% aqueous NH4HCO3 from a
Macherey-Nagel SS 250/0.5 in.′′/10-nucleosil 300-7 C18
Scheme 1
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reverse phase column; retention time 5.2 min at a flow rate
of 3 mL/min). FTIR (KBr, cm-1) 1761, 1658, 1590. 1H NMR
(D2O) ä: 1.14-1.28 (2H, m), 1.36 (3H, s), 1.42-1.56 (2H,
m), 1.50 (3H, s), 1.6-1.76 (2H, m), 2.20 (2H, ABX2, J )
6.3, 7.3 Hz), 3.54 (1H, t, J ) 6 Hz), 4.08 (1H, s), 5.31 (1H,
d, J ) 3.9 Hz), 5.40 (1H, d, J ) 3.9 Hz). ES(+) MS m/e:





Nitrobenzyloxycarbonyl)-D-R-aminopimelic acid (50 mg,
91.6 ímol) and diphenylmethyl 7-aminocephalosporanate
(43) (35.6 mg, 76.3 ímol) were dissolved in 2 mL of
anhydrous DMF and cooled to 0 °C in an ice bath. To this
solution were added 1-hydroxybenzotriazole (14.0 mg, 107
ímol) and EDC (17.6 mg, 91.6 ímol), and the reaction was
stirred for 6 h at room temperature. It was then evaporated
to dryness by means of a vacuum pump. The residue was
dissolved in ethyl acetate and washed successively with equal
portions of 10% aqueous citric acid, water, saturated aqueous
NaHCO3, water, and brine. After evaporation of the organic
solvent, the product was purified by preparative TLC on
silica gel, with 50/50 acetone/hexane as solvent. The product
was extracted from the plate with ethyl acetate in 47 mg
(61%) yield. 1H NMR (CD3CN) ä: 1.22-1.36 (2H, m),
1.39-1.56 (2H, m), 1.60-1.78 (2H, m), 1.94 (3H, s), 2.24
(2H, t, 6.8 Hz), 3.55 (2H, ABq, J ) 19.2 Hz), 4.26 (1H, m),
4.78 (2H, ABq, J ) 12.9 Hz), 5.07 (1H, brs), 5.22 (2H, s),
5.26 (2H, s), 5.80 (1H, br s), 6.25 (1H, br d), 6.86 (1H, br
d), 6.92 (1H, s), 7.3-7.48 (10H, m), 7.58 (4H, d, J ) 7.3
Hz), 8.22 (4H, d, J ) 7.3 Hz).
p-Nitrobenzyl 7-â[N-(p-Nitrobenzyloxycarbonyl)-D-R-ami-
nopimelyl]-aminocephalosporanic Acid. The triprotected
cephalosporin from above (47.6 mg) was stirred in trifluo-
roacetic acid (2 mL) at room temperature for 30 min. The
acid was then removed by evaporation under vacuum, and
the residue was partitioned between an aqueous layer
containing NaHCO3 (3 equiv) and ethyl acetate. The aqueous
extraction was repeated twice, and the ethyl acetate layer
was then dried (MgSO4) and evaporated to dryness. The solid
residue was further dried on a vacuum pump, extracted with
benzene (the benzene extract discarded), and dried again;
yield 25 mg (64%). 1H NMR (CDCl3) ä: 1.22-1.36 (2H,
m), 1.39-1.56 (2H, m), 1.60-1.78 (2H, m), 1.94 (3H, s),
2.24 (2H, t, J ) 6.8 Hz), 3.55 (2H, ABq, J ) 19.6 Hz), 4.26
(1H, m), 4.78 (2H, ABq, J ) 14.8 Hz), 5.03 (1H, d, J ) 4.3
Hz), 5.20 (2H, s), 5.27 (1H, s), 5.80 (1H, (ABq), J ) 4.3
Hz), 7.14 (1H, d, J ) 7.3 Hz), 7.60 (4H, d, J ) 7.3 Hz),
8.24 (4H, d, J ) 7.3 Hz).
7-â(D-R-Aminopimelyl)-aminocephalosporanic Acid (14).
p-Nitrobenzyl 7-â[N-(p-nitrobenzyloxycarbonyl)-D-R-ami-
nopimelyl]-aminocephalosporanic acid (27.1 mg, 30.2 ímol)
was dissolved in a solution of sodium bicarbonate (16.1 mg,
192 ímol, 2 equiv) in THF (16.4 mL) and water (8.2 mL).
After addition of 10% Pd-C (159 mg) to the mixture, it
was hydrogenated under 1 atm pressure at room temperature
for 0.5 h. The resulting suspension was filtered through a
Celite pad into a cooled flask, and the filtered solid was
washed with ethanol (8.2 mL) and water (8.2 mL). The
combined filtrate was extracted with diethyl ether (2  3.1
mL) and the aqueous layer freeze-dried, yielding a pale
yellow solid. This salt was purified by hplc (elution by 4%
methanol in 0.03% aqueous NH4HCO3 from a Macherey-
Nagel SS 250/0.5 in./10-nucleosil 300-7 C18 reverse phase
column; retention time 12 min at a flow rate of 3 mL/min);
yield 7.6 mg (55%). FTIR (KBr, cm-1): 1750, 1666, 1625.
1H NMR (D2O) ä: 1.16-1.32 (2H, m), 1.44-1.54 (2H, m),
1.62-1.74 (2H, m), 1.92 (3H, s), 2.18 (2H, ABX2, J ) 4.6,
7.4 Hz), 3.34 (2H, ABq, J ) 18.0 Hz), 3.55 (1H, t, J ) 5.8
Hz), 4.60 (2H, ABq, J ) 13.0 Hz), 4.93 (1H, d, J ) 4.5
Hz), 5.46 (1H, d, J ) 4.5 Hz). ES(+) MS m/e: 452.5, [M
+ Na]+.
6-â-(N-Acetyl-L-alanyl-ç-D-glutamyl-L-alanyl)-aminopeni-
cillanic Acid (16) (Scheme 3).
ç-tert-Butyl R-p-Nitrobenzyl-N-Boc-D-glutamate. The start-
ing material, Boc-D-R-Glu-OtBu, was dried overnight under
vacuum in the presence of P2O5. Dicyclohexylamine (1.2
mL, 9.9 mmol) was added to a solution of this dried sample
(3 g, 9.9 mmol) in DMF (21 mL) at 75-85 °C (internal
temperature). A solution of 2.14 g of p-nitrobenzyl bromide
(9.9 mmol) in DMF (5 mL) was added in a single portion to
the hot solution, which was stirred for 5 min. A precipitate
immediately separated, the mixture was cooled to room
temperature, and ethyl acetate (10 mL) was added. The
precipitate was removed by filtration and the ethyl acetate
solution washed with water, saturated aqueous NaCl, and
saturated aqueous NaHCO3, dried over MgSO4, and evapo-
rated in Vacuo to leave a yellow solid, which contained the
required product along with some p-nitrobenzyl alcohol. The
quantity of the required product was estimated to be 2.6 g
(59%). 1H NMR (d6-DMSO) ä: 1.34 (9H, s), 1.66-1.84
(1H, m), 1.84-2.0 (1H, m), 2.24 (2H, t, J ) 7.3 Hz), 4.06
(1H, q, J ) 7.2 Hz), 5.26 (2H, s), 7.36 (1H, d, J ) 8.2 Hz),
7.71 (2H, d, J ) 8.2 Hz), 8.21 (2H, d, J ) 8.2 Hz).
R-p-Nitrobenzyl D-Glutamate. The crude triprotected
glutamate from above (3.54 g) was dissolved in CH2Cl2 (10.6
mL) and cooled to 0 °C, and TFA (53 mL) was slowly added.
After complete addition, the solution was stirred for 2 h at
room temperature. The TFA was removed by rotary evapo-
Scheme 2
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ration and the residue further dried overnight under an oil
pump vacuum.
R-p-Nitrobenzyl N-Boc-L-Alanyl-D-glutamic acid. A solu-
tion of R-p-nitrobenzyl D-glutamate (2.28 g, 8.09 mmol) and
Boc-Ala-OSu (1.5 g, 5.09 mmol) in DME (11 mL) was
mixed with NaHCO3 (4 equiv, 32.3 mmol) in water (34 mL)
at room temperature. This suspension was stirred overnight.
To remove p-nitrobenzyl alcohol, the reaction mixture was
extracted with ethyl acetate. It was then acidified at 4 °C
with phosphoric acid to pH 2. Acidification was followed
by several extractions with ethyl acetate. The combined ethyl
acetate extracts were washed twice with water and dried over
anhydrous Na2SO4. After evaporation of the solvent, the yield
of the required product was 2.4 g, 100%. 1H NMR (d6-
DMSO) ä: 1.16 (3H, d, J ) 7.2 Hz), 1.34 (9H, s), 1.76-
1.92 (1H, m), 1.92-2.08 (1H, m), 2.26 (2H, t, J ) 6.9 Hz),
3.98 (1H, m), 4.34 (1H, AXY, J ) 5.1, 8.9 Hz), 5.25 (2H,
s), 6.91 (1H, d, J ) 7.6 Hz), 7.62 (2H, d, J ) 8.6 Hz), 8.22
(2H, d, J ) 8.6 Hz), 8.25 (1H, d, J ) 6.9 Hz).
R-p-Nitrobenzyl N-Boc-L-Alanyl-D-ç-glutamyl-L-alanine
tert-Butyl Ester. R-p-Nitrobenzyl N-Boc-L-alanyl-D-ç-glutam-
ic acid (2.45 g, 5.40 mmol) and AlaOtBuâHCl (981 mg, 5.40
mmol) were dissolved in DMF and cooled to 0 °C in an ice
bath. To this solution was added triethylamine (756 íL, 5.40
mmol), and the mixture was stirred well, while a precipitate
formed. At this stage, 1-hydroxybenzotriazole (875 mg, 6.48
mmol) was added. The mixture was stirred for 5 min and
EDC (1.04 g, 5.4 mmol) added. The final reaction mixture
was stirred at room temperature for 18 h. It was then
evaporated to dryness with a vacuum pump. The residue was
dissolved in ethyl acetate. This solution was washed suc-
cessively with equal portions of 10% citric acid, water,
saturated NaHCO3, water, and brine and dried over anhy-
drous Na2SO4; yield 2.5 g, 95%. 1H NMR (d6-DMSO, 300
MHz) ä: 1.18 (3H, d, J ) 7.0 Hz), 1.21 (3H, d, J ) 7.0
Hz), 1.43 (18H, s), 1.78-1.92 (1H, m), 1.92-2.07 (1H, m),
2.15 (2H, t, J ) 6.0 Hz), 3.96-4.14 (2H, 2 sets of
overlapping quartets), 4.26-4.36 (1H, q, J ) 6.0 Hz), 5.25
(2H, s), 6.89 (1H, d, J ) 7.2 Hz), 7.62 (2H, d, J ) 8.4 Hz),
8.13 (1H, d, J ) 7.2 Hz), 8.21 (2H, d, J ) 8.4 Hz), 8.28
(1H, d, J ) 7.2 Hz).
R-p-Nitrobenzyl L-alanyl-D-ç-glutamyl-L-alanine. The pro-
tected tripeptide (481 mg, 0.83 mmol) was dissolved in the
minimum volume (e2 mL) of CH2Cl2. The solution was
chilled to 0 °C in an ice bath with constant stirring. TFA
(10.5 mL) was added slowly to the above solution. After
the addition was complete, the reaction mixture was stirred
for 2 h at room temperature. TFA was then removed by
rotary evaporation. The required compound R-p-nitrobenzyl
L-alanyl-D-ç-glutamyl-L-alanine was dried overnight on the
vacuum pump.
R-p-Nitrobenzyl N-Acetyl-L-alanyl-D-ç-glutamyl-L-alanine.
Here we followed the acetylation procedure of Meroueh et
al. (44). The crude residue from the previous step was
dissolved in DMF (18.6 mL). To this solution were added
triethylamine (448 íL, 3.32 mmol) and acetic anhydride 258
íL, 0.91 mmol), and the resultant mixture was stirred at room
temperature overnight. The solvent was removed under
vacuum. The residue was dissolved in ethyl acetate, washed
with 10% citric acid followed by water, dried over anhydrous
Na2SO4, and evaporated to dryness. The N-acetylated tri-
peptide was purified by silica gel column chromatography
using 60/35/5 acetone/hexane/methanol as eluent; yield, 64.3
mg, 74%. 1H NMR (d6-DMSO) ä 1.22 (3H, d, J ) 7.2 Hz),
1.17 (3H, d, J ) 7.2 Hz), 1.82 (3H, s), 1.78-1.92 (1H, m),
1.92-2.07 (1H, m), 2.16 (2H, t, J ) 7.5 Hz), 4.14 (1H, quint,
J ) 6.9 Hz), 4.22-4.33 (2H, m), 5.24 (s, 2H), 7.62 (2H, d,
J ) 8.4 Hz), 8.06 (1H, d, J ) 8.0 Hz), 8.13 (1H, t, J ) 7.2
Hz), 8.22 (2H, d, J ) 8.7 Hz), 8.44 (1H, d, J ) 4.8 Hz).
6-â[R-p-Nitrobenzyl N-Acetyl-L-alanyl-ç-D-glutamyl-L-ala-
nyl]-aminopenicillanic Acid p-Nitrobenzyl Ester. R-p-Ni-
trobenzyl-N-acetyl-L-alanyl-D-ç-glutamyl-L-alanine (500 mg,
1.11 mmol) and p-nitrobenzyl 6-aminopenicillanate (42) (338
mg, 0.922 mmol) were dissolved in 5 mL of anhydrous DMF
and cooled to 0 °C in an ice bath. To this solution were
added 1-hydroxybenzotriazole (174 mg, 1.29 mmol) and
Scheme 3
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EDC (565 mg, 2.95 mmol), and the reaction mixture was
stirred for 5 h at room temperature. The solution was then
evaporated to dryness under vacuum. The residue was
dissolved in ethyl acetate and washed successively with equal
portions of citric acid, water, saturated aqueous NaHCO3,
and water, followed by brine. The ethyl acetate was dried
and evaporated. Product yield: 158 mg (100%). 1H NMR
(d6-DMSO) ä: 1.14 (6H, 2 overlapping d, J ) 6.9 Hz), 1.35
(3H, s), 1.55 (3H, s), 1.95 (3H, s), 2.0 (2H, br s), 2.16 (2H,
br s), 3.98 (1H, q, J ) 7.2 Hz), 4.2-4.4 (overlapping q and
m, 2H), 5.22 (2H, s), 5.32 (2H, s), 4.55 (1H, s), 5.49 (1H, d,
J ) 4.2 Hz), 5.55 (1H, d, J ) 4.2 Hz), 7.59 (2H, d, J ) 8.7
Hz), 7.68 (2H, d, J ) 6.6 Hz), 8.02 (1H, d, J ) 7.8 Hz),
8.18-8.24 (2 overlapping d, 4H), 8.39 (1H, d, J ) 7.5 Hz),
8.56 (1H, d, J ) 7.5 Hz).
6-â(N-Acetyl-L-alanyl-ç-D-glutamyl-L-alanyl)-aminopeni-
cillanic Acid (16). The protected penicillin from above (158
mg, 0.2 mmol) was dissolved in freshly distilled THF (34
mL) and water (30 mL) containing NaHCO3 (43.6 mg, 0.5
mmol). When the mixture became homogeneous, 10% Pd-C
(315 mg) was added, and it was hydrogenated under 1 atm
pressure at room temperature for 2.5 h. The suspension was
filtered through Celite into a chilled receiving flask and the
residue washed with ethanol (20 mL) and water (30 mL).
The pH of the filtrate was checked to ensure that it was
neutral or weakly basic. The filtrate was extracted with
diethyl ether. After the extractions, the aqueous phase pH
was checked again and found to be neutral. The aqueous
phase was then freeze-dried to leave a pale yellow solid.
This salt was purified by hplc (elution by 1% methanol in
0.03% aqueous NH4HCO3 from a Macherey-Nagel SS250/
0.5 in./10-nucleosil 300-7 C18 reverse phase column; retention
time 7.74 min at a flow rate of 3 mL/min); yield 15.3 mg.
1H NMR (D2O) ä: 1.23 (3H, d, J ) 7.1 Hz), 1.25 (3H, d,
J ) 7.1 Hz), 1.37 (3H, s), 1.48 (3H, s), 1.90 (3H, s), 1.74-
1.88 (1H, m), 1.96-2.10 (1H, m), 2.19 (2H, t, J ) 7.5 Hz),
4.12 (1H, s), 4.15-4.20 (3H, m), 5.32 (1H, d, J ) 3.9 Hz),
5.42 (1H, d, J ) 4.2 Hz). ES(-) MS m/e: 528.3, [M - 1].
Penicillins 15 and 17, the cephalosporin 18, and the peptide
3 were prepared by routes analogous to those above, as
described in the Supporting Information. The peptide 19 was
purchased from Sigma-Aldrich Corp.
Kinetics Studies
Materials. A purified sample of E. coli PBP 2 was obtained
from Dr. H. Adachi (University of Tokyo, Tokyo, Japan).
S. pneumoniae PBP 2x, PBP 1b, and PBP 3 (10-12) and E.
coli PBP 5 (13) were prepared as described, as was the
Actinomadura R39 DD-peptidase (15). The S. pneumoniae
enzymes were generous gifts of Dr. Otto Dideberg and Dr.
Andrea Dessen of CNRS/CEA/UJF, Grenoble, France.
E. coli PBP 2 and PBP 5. Rate constants for inhibition of
PBP5 by 13-16 were obtained from competition experiments
with the chromophoric substrate N-phenylacetylglycyl-D-
thiolactate (20). Turnover of 20 (500 íM) was monitored
spectrophotometrically at 257 nm (¢ ) 1.04  103 cm-1
M-1) in a 0.1 M sodium pyrophosphate buffer containing
10% glycerol, pH 8.5, at 37 °C. The enzyme concentration
was 0.74 íM, and the â-lactam concentrations varied
between 0 íM and 50 íM. The total progress curves obtained
were analyzed by means of the Dynafit program (45) and
Scheme 4 (S and I represent 20 and the â-lactam, respec-
tively; kcat/Km ) 550 s-1 M-1).
For PBP 2, competition between 13 and the chromogenic
â-lactam 6â-bromopenicillanic acid was monitored spectro-
photometrically at 325 nm (¢ ) 6.1  103 cm-1 M-1) (46).
The buffer employed was 20 mM Hepes/0.2 M NaCl, pH
8.0. Concentrations of bromopenicillin and enzyme were 100
íM and 4.1 íM, respectively, and concentrations of 13 were
0-1.0 mM. Experiments were performed at 37 °C, and the
total progress curves were fitted to Scheme 5 (I and I′
represent 13 and bromopenicillin, respectively.) The value
of ki′ for bromopenicillin was 33 s-1 M-1.
S. pneumoniae PBP 1b, PBP 2x, and PBP 3. Acylation
of the active sites of PBP 2x (9, 26) and PBP 1b (47) is
accompanied by a decrease in protein fluorescence. There-
fore, in these cases, determinations of ki could be made by
direct measurement. For PBP 2x, excitation and emission
wavelengths were 290 and 340 nm, respectively, while, for
PBP 1b, the corresponding wavelengths were 290 and 350
nm, respectively. Thus, changes in the fluorescence emission
of PBP 2x (0.26 íM) with time on addition of 17 (0.3-0.6
íM) were monitored directly. The reaction conditions were
10 mM phosphate/500 mM KCl buffer, pH 7.0, 37 °C. Total
progress curves were fitted to Scheme 6. Experiments with
PBP 1b were carried out in 20 mM Hepes/0.1 M NaCl/1
mM EDTA buffer, pH 7.0 and at 25 °C. Concentrations of
enzyme and the â-lactams 17 and 18 were 0.56 íM and
2-100 íM, respectively.
The fluorescence spectrum of PBP 3 did not appear to
change on addition of â-lactams. Therefore, competition
experiments with the substrate 20 (0.5 mM) were performed
as described above. The reaction conditions were 20 mM
Hepes, 1 mM EDTA buffer, pH 7.0, 37 °C. Reaction
mixtures contained enzyme (53 nM) and the â-lactams 17
and 18 (200-400 nM). The resulting total progress curves
were analyzed in terms of Scheme 4.
The reactivity of PBP 3 and PBP 1b with the peptides 5
and 6 was assessed spectrophotometrically at 220-235 nm
(29) in the Hepes buffer described immediately above, at
37 °C. Concentrations of PBP 3 were 53 nM and 10.5 íM
and of PBP 1b 0.56 íM; peptide concentrations were 1-10
mM.
Actinomadura R39 DD-Peptidase. Rate constants of inhibi-
tion of the R39 DD-peptidase by the â-lactams 13-15 were
obtained from competition experiments employing the pep-
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reaction conditions were 25 mM Tris/1.25 mM MgCl2 buffer,
pH 7.7, 37 °C. Under these conditions, the Km value of 3
was 4.0 íM. For studies with 13 (50-60 nM), the enzyme
concentration was 35 nM, and with 14 (10-20 nM) and 15
(50 nM), the enzyme concentration was 18.3 nM. Total
progress curves were fitted to Scheme 4.
Where necessary for comparison, the inhibition rate
constants for benzylpenicillin and cephalothin were obtained
from experiments analogous to those described above.
RESULTS AND DISCUSSION
The synthesis of the â-lactams 13-18 has been achieved
by classical peptide chemistry, as described above. The side
chain present in 13 and 14 is a direct mimic of the
nucleophilic fork of the stem peptides of E. coli (1) and
Actinomadura (9), respectively. The â-lactam in each case
is, of course, an analogue of the D-alanyl-D-alanine C-
terminus (4, 37). The penicillin 15 is analogous to 13 and
designed for the enzymes of the same species, but with the
aliphatic methylene chain one carbon longer to allow greater
flexibility. Penicillin 16, where the side chain imitates the
general stem peptide fork leading to NAM, was also
designed, by virtue of the D-isoglutamic acid residue, as a
probe of E. coli enzymes. Finally, 17 and 18 were designed
to challenge the active sites of S. pneumoniae enzymes.
â-Lactams with peptide side chains have been prepared
previously by others, but they were not assessed as inhibitors
of specific enzymes (48, 49).
An example of the data used to obtain the inhibition rate
constant ki for inactivation of E. coli PBP 5 by the penicillin
13 is shown in Figure 1. This shows the results of a
competition experiment where 13 and the reporter substrate
20 compete for the enzyme. The enzyme is obviously
inhibited to some degree, but complete turnover of the
substrate occurred because of the well-known significant
ability of this particular PBP to catalyze hydrolysis of the
penicilloyl-enzyme and thus hydrolyze the penicillin (50, 51).
The rate constants describing the interaction between 13 and
the enzyme were obtained by fitting the data to Scheme 4,
as described in Materials and Methods. The reaction between
S. pneumoniae PBP 1b and the penicillin 14 was monitored
directly by fluorescence changes (Figure 2). Figure 3 shows
the results of a competition experiment between the peptide
substrate 3 and the penicillin 13 for the R39 DD-peptidase.
In this case, as is more typical, acylation by 13 was fast and
turnover very slow. At the concentrations employed in all
of these experiments, only second order inactivation reactions
were observed.
The results of experiments, such as described above,
designed to measure second order rate constants of inactiva-
tion (ki) of the panel of enzymes by 13-18, are shown in
Table 1. For each enzyme, for comparison, the inactivation
rate constants for the generic â-lactams, benzylpenicillin (21)
and cephalothin (22), are also reported. The general result
for the HMW PBPs (classes A and B) was that the “specific”
peptidoglycan-mimetic â-lactams reacted more slowly with
their respective enzymes than did their generic analogues.
FIGURE 1: Reaction of E. coli PBP5 (0.74 íM) with the depsipep-
tide substrate 20 (0.5 mM), monitored spectrophotometrically at
257 nm, in the absence (4) and presence (O) of the penicillin 13
(20 íM). The points shown are experimental and the lines calculated
as described in the text.
FIGURE 2: Reaction of S. pneumoniae PBP1b (0.56 íM) with the
penicillin 17 (20 íM), monitored fluorimetrically at 350 nm
(excitation at 290 nm). The points shown are experimental and the
line is calculated as described in the text.
FIGURE 3: Reaction of R39 DD-peptidase (35 nM) with the peptide
substrate 3 (0.25 mM), monitored spectrophotometrically at 220
nm, in the absence (4) and presence (O) of the penicillin 13 (50
nM). The points shown are experimental and the lines calculated
as described in the text.
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This result also applied, generally, to the class A LMW
enzymes. An exception to this generalization is the greater
reactivity of the cephalosporin 14 than cephalothin with E.
coli PBP 5. This result is interesting, although 14 is only
slightly more reactive than the penicillin 13 and the differ-
ence between the rates with 14 and cephalothin is not as
great as observed in other cases (see below). The greater
flexibility of 15, designed to allow it a greater chance of
reaching specific polar functional groups at the active site
of E. coli PBPs, provided little enhanced reactivity. The
penicillin 16 reacted more slowly with E. coli PBP 5 than
13, showing that the segment of stem peptide reproduced in
the side chain of 16 had even less affinity for the enzyme
than did that of the N-terminus present in 13.
The low reactivity of the PBPs described in the preceding
paragraph with specific â-lactams is mirrored by their low
reactivity with the corresponding specific peptides. For
example, neither PBP 2 nor PBP 5 of E. coli catalyzes
hydrolysis of 3 at any appreciable rate; nor does S. pneu-
moniae PBP 2x catalyze hydrolysis of 5 (29). E. coli PBP 5
shows modest activity against 4, but neither E. coli PBP 2
nor S. pneumoniae PBP2x hydrolyzes 4 or 6, respectively
(29). As part of the present work, we have found that S.
pneumoniae PBP 1b and PBP 3 do not catalyze hydrolysis
of the peptides 5, 6, and 19.
A very different result is obtained when the LMW class
B and C enzymes are considered. As previously described
(38), both 12 and the cephalosporin 23 react at least 2 orders
of magnitude more rapidly than the respective generic
â-lactams with the R61 DD-peptidase. A similar result is now
seen in the reactivity of 13 and 14 with the R39 DD-peptidase,
suggesting, as with the R61 enzyme, the presence of specific
interactions of the side chain with the R39 active site. The
extended and more flexible analogue of 13, the penicillin
15, reacts somewhat more slowly than 13 with the R39 DD-
peptidase. This result suggests that the optimal side chain
length is indeed found in 13. A similar effect of extended
chain length was also observed with the R61 enzyme (52).
As noted previously, these enzymes also catalyze hydrolysis
of the peptides 3 (R39) and 7 (R61) very efficiently (29,
34).
There appears to be, taking into account all of the enzymes
considered above, a direct correlation between the effect of
a peptidoglycan-mimetic side chain on the reactivity of a
â-lactam and that of a D-alanyl-D-alanine peptide. Specifi-
cally, there is little side chain effect, on either â-lactam or
peptide reactivity, with HMW PBPs or class A LMW PBPs.
In contrast, such a side chain has a dramatic positive effect
on the reactivity of both a â-lactam and peptide with a class
B or C LMW PBP. As described in the introduction, crystal
structures show that the peptidoglycan-mimetic side chain
of peptide 7 and the â-lactam 12 interact with the R61 DD-
peptidase active site in what appears to be a tight and specific
fashion. We conclude from the results described above that
a specific side chain binding site must also be directly
available in the R39 DD-peptidase active site, but not in the
other enzymes employed in this study. X-ray crystallographic
studies of appropriate complexes to examine these predictions
are in progress.
There appear to be two possible explanations for the
unexpected lack of recognition of stem peptide elements by
the majority of the PBPs noted above. In these cases, either
the region of the enzyme’s active site specific to these
elements is distorted or incomplete or the substrate recogni-
tion elements are elsewhere on the protein. These alternatives
and their implications for future research are discussed below.
First, with respect to the enzyme active site, it may be
noted that although there is no direct structural evidence at
present for the presence or absence of peptidoglycan-mimetic
side chain binding sites in these enzymes, apart from the
R61 DD-peptidase (36, 39), the general lack of reactivity of
the solubilized constructs of these enzymes is striking. On
one hand, they do, in general, react with â-lactams but, on
the other, appear, at best, sluggishly reactive with peptides.
Studies of these enzymes under conditions designed to
mimic those in ViVo, e.g. as membrane fragments solubilized
in detergents, or in mixed organic/aqueous solvents, have
also yielded equivocal results. Although, under these condi-
tions, a number of PBPs have been able to catalyze cross-
linked peptidoglycan synthesis using undecaprenyl pyro-
phosphoryl disaccharide pentapeptide or disaccharide penta-
peptide as substrate, the rates observed were much lower
than required for bacterial growth rates (21-25). In explana-
tion of these results, it has been suggested that the correct
in ViVo medium for these enzymes has not yet been
reproduced, and, more particularly, that the likelihood that
Table 1: Rate Constants for Inactivation of Penicillin-Binding
Proteins by â-Lactams
PBP (class)
(source) â-lactam ki (s-1 M-1)
PBP1b (HMW, A) benzylpenicillin (1.30 ( 0.07)  104
(S. pneumoniae) 17 95 ( 16
cephalothin (91 ( 3)  103
18 34 ( 9
PBP 2x (HMW, B) benzylpenicillin (1.3 ( 0.3)  104
(S. pneumoniae) 17 (3.9 ( 1.3)  103
PBP 2 (HMW, B) benzylpenicillin 190 ( 60
(E. coli) 13 e25
PBP 5 (LMW, A) benzylpenicillin (8.01 ( 0.23)  103
(E. coli) 13 (2.16 ( 0.04)  103
15 (3.06 ( 0.14)  103
16 (5.80 ( 0.22)  102
cephalothin (1.75 ( 0.05)  102
14 (4.7 ( 0.9)  103
PBP 3 (LMW, A) benzylpenicillin (3.0 ( 0.9)  104
(S. pneumoniae) 17 (1.20 ( 0.16)  104
R61 (LMW, B) benzylpenicillin 1.37  104 a
(Streptomyces R61) 12 1.5  107 a
cephalothin 1.4  103 a
23 5.6  105 a
R39 (LMW, C) benzylpenicillin 3  105 b
(Actinomadura R39) 13 (6.8 ( 0.3)  106
15 (2.85 ( 0.09)  106
cephalothin 6.5  104 b
14 (1.1 ( 0.4)  107
a Taken from ref 38. b Taken from ref 68.
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these enzymes in ViVo act as components of multiprotein
complexes has not been sufficiently taken into account (53-
55). There is evidence for association in solution of certain
E. coli PBPs (56, 57 and references therein), and the
transpeptidase activity of E. coli PBP1b appears to be greater
when the enzyme is in dimeric form (25). It also appears
well-established that E. coli PBP 2 is activated by the
presence of the integral membrane protein rodA (58, 59). It
should also be noted that, in ViVo, most PBPs, and certainly
the lethal targets for â-lactams (HMW class A and B
enzymes), are membrane-associated by an N-terminal pep-
tide, and, in the case of HMW class A PBPs, by a secondary
membrane association site located in the glycosyl transferase
domain (60, 61). Thus, there is certainly reason to believe
that the structure of the extended active site of a PBP, both
as a static and a dynamic entity, and therefore the enzyme
activity, could be significantly different when present in
solubilized transpeptidase domains in aqueous solution or
in the crystal form from that in ViVo. It does seem, however,
that generic non-peptidoglycan-mimetic â-lactams react with
PBPs in ViVo as rapidly as with purified enzymes (32, 33);
indications of lower reactivity may derive from the presence
of â-lactamases (55). This shows that although the specific
recognition elements for natural substrates may not be present
in the solubilized enzymes, the chemically reactive active
site center is always present and, in solution, functional.
It is possible that, just as the active sites of these enzymes
may be organized in ViVo to react with peptide substrates
rapidly, so they might also react rapidly in ViVo with
peptidoglycan-mimetic â-lactams such as 13-18. Experi-
ments to test this proposition are in progress.
It should be recalled at this point that the soluble
Actinomadura R39 DD-peptidase, found to be an active DD-
peptidase and rapidly inactivated by 13 and 14, has an amino
acid sequence and tertiary structure homologous to E. coli
PBP 4 (15, 16), which is, in ViVo, a soluble protein only
loosely associated with the cell membrane (62, 63); the
Streptomyces R61 DD-peptidase, as isolated, is also a water
soluble protein. These enzymes, therefore, may be isolated
in the complete active form and remain in that form.
A second explanation for the curious insensitivity of most
PBPs to peptidoglycan mimetics is that an essential element
of substrate recognition in ViVo is centered at a region of
the enzyme other than the transpeptidase active site. This
implies that effective substrates may be larger than the
molecules described here, and this is certainly conceivable
since a likely substrate of many of these enzymes is the
peptidoglycan polymer. Activation of enzymes by exosite
recognition is well-known (64, 65). The disaccharide pen-
tapeptide itself (23) and its synthetic analogues (30),
however, are apparently not large enough to achieve sig-
nificant recognition. Perhaps a contribution from an adjacent
peptidoglycan strand is required. There is some evidence for
additional binding sites on certain PBPs, although only weak
binding has been found to date (66, 67). It may also be that
different PBPs are activated by different elements of extended
structure.
A combination of the results from this paper and from an
earlier one (29) demonstrates that peptidoglycan-mimetic side
chains have similar effects on the kinetics of reaction of both
peptides and â-lactams with DD-peptidases. In certain cases
(LMW class B and C enzymes), these side chains have a
dramatic positive effect on reactivity, while in others (LMW
class A and HMW enzymes) they have little or no effect.
With respect to the latter group of enzymes, which include
essentially all of the important â-lactam killing targets, the
result is certainly a curious and unexpected one: the enzymes
appear to show no specificity toward local peptidoglycan
structure. The possible explanations for this are discussed
above: the enzymes and/or the substrates are incomplete in
some way that prevents them under in Vitro conditions from
behaving as they must in ViVo. At this stage, therefore,
because of the apparent absence of specific side chain binding
sites in these latter enzymes, it is unclear whether chemical
and structural studies in Vitro can directly lead to new
antibiotics. Much remains to be done for us to understand
the action of these enzymes in ViVo.
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